[vc_row thb_full_width=”true” content_placement=”middle” thb_shape_divider=”true” el_id=”interior_header” css=”.vc_custom_1596656423052{margin-bottom: 60px !important;background-image: url(https://zalgen.com/wp-content/uploads/new-hp-banner.png?id=2461) !important;background-position: center !important;background-repeat: no-repeat !important;background-size: cover !important;}” divider_shape=”waves” thb_divider_color=”#ffffff” thb_divider_height=”50″][vc_column][vc_row_inner content_placement=”middle” el_id=”hp_hero_wrapper”][vc_column_inner][vc_column_text]

Science Leadership

[/vc_column_text][/vc_column_inner][/vc_row_inner][/vc_column][/vc_row][vc_row thb_full_width=”true” bg_gradient_direction=”0″ thb_shape_divider=”true” bg_gradient1=”#ffffff” bg_gradient2=”#f7f7f7″ divider_shape=”waves_v2″ thb_divider_color=”#ffffff”][vc_column][vc_row_inner el_id=”interior-content”][vc_column_inner width=”3/4″ el_id=”interior-text”][vc_column_text]

Zalgen is on the cutting edge of viral hemorrhagic fever products discovery and development.

Our scientific team, advisors and collaborators have the experience and know-how to navigate through this difficult environment in a very efficient manner that will bring to market numerous innovative and useful products critical to combat these fevers and related neglected tropical diseases.

Led by Dr. Robert F. Garry, Zalgen programs cover three important business areas — vaccines, immunotherapeutics and diagnostics — all utilizing proprietary recombinant technology and platform experience resulting in solutions addressing critical medical needs.[/vc_column_text][vc_separator css=”.vc_custom_1568666353309{padding-top: 60px !important;}”][vc_column_text]

Robert F. Garry, Ph.D.
Chief Scientific Advisor

B.S. (1974) Indiana State University, Life Sciences
Ph.D. (1978) University of Texas at Austin, Microbiology
Postdoctoral Research (1978-82) University of Texas at Austin

Dr. Garry is the President of the Viral Hemorrhagic Fever Consortium (VHFC), a non-profit consortium of scientists developing countermeasures including diagnostics, immunotherapeutics and vaccines, against Lassa virus, Ebola and Marburg viruses and other high consequence pathogens. Dr. Garry serves in the Tulane University administration as Assistant Dean for Graduate Studies in Biomedical Sciences and is the founding Editor-in-Chief of Virology Journal.[/vc_column_text][vc_separator css=”.vc_custom_1568666353309{padding-top: 60px !important;}”][vc_column_text]

Luis M. Branco, Ph.D.
Program Director: Immunotherapeutics

B.S. (1995) University of Massachusetts at Amherst, Microbiology
Ph.D. (2010) Tulane University, Biomedical Sciences

In his 25+ years in the immunotherapeutic industry Dr. Branco has been directly involved in the development of numerous licensed antibody therapeutics, including MedImmune’s Synagis (Palivizumab), Human Genome Sciences’ (HGSI) Benlysta (Belimumab) and ABthrax  (raxibacumab), as well as additional antibodies under clinical evaluation. He is a co-founder of Zalgen and is the patent holder of CHOLCelect, a unique mammalian cell-based biomanufacturing system which generates highly regulatory compliant NS0 stable cell lines.[/vc_column_text][vc_separator css=”.vc_custom_1568666353309{padding-top: 60px !important;}”][vc_column_text]

Matthew L. Boisen, Ph.D.
Program Director: Diagnostics

B.S. (1990) San Jose State University, Immunology & Medical Microbiology
Ph.D. (2015) Tulane University, Biomedical Sciences

Dr. Boisen has over 25 years’ experience in IVD product development with expertise in rapid, point-of-care diagnostics for detection of infectious diseases and biowarfare agents. With a broad background in diagnostic methodology including Lateral Flow Immunoassay, ELISA, optical biosensors, and micro-array platforms that span manual, semi-automated, and fully automated operation, Dr. Boisen is the Site Manager for the Zalgen Advanced Diagnostics Technology Center in Aurora, CO.[/vc_column_text][vc_separator css=”.vc_custom_1568666353309{padding-top: 60px !important;}”][vc_column_text]

Anatoliy Koval, Ph.D.
Program Director: Vaccines

B.S. (1982) Kiev State University, Organic Chemistry
M.S. (1983) Kiev State University, Chemistry
Ph.D. (1992) Institute of Molecular Biology and Genetics, Ukrainian Academy of Sciences
Postdoctoral Research (1993-1998) National Institutes of Health

Dr. Koval has over 30 years of experience in the fields of molecular and cellular biology. At Zalgen Labs, he is developing Lassa GPC MARMs and neutralization assays using the VSV-LASV-G virus system. In addition, he plays a leading role in development and manufacturing of novel LASV and EBOV vaccines based on a promising recombinant VSV platform. Prior to joining Zalgen, Dr. Koval executed and managed multiple projects at Lonza Walkersville. His major expertise led in developing and commercialization of products based on human primary cell systems including stem cells, genetically engineered human cell lines, and cell-based assays.[/vc_column_text][vc_separator css=”.vc_custom_1568666353309{padding-top: 60px !important;}”][vc_column_text]

Raju Lathigra, Ph.D.
Program Director: Molecular Biology

B.Sc. (1975) Sardar Patel University, Microbiology
M.Sc. (1978) Maharaja Sayajirao University, Microbiology
Ph.D. (1983) Queen Mary, University of London, Microbiology and Molecular Biology

Dr. Lathigra is involved in developing bispecific antibodies against LASV and EBOV as second and potentially 3rd generation therapeutics based on Arevirumab and EBOLA antibodies. At MedImmune he was also involved in engineering second generation derivatives of Synagis. Dr. Lathigra has over 30 years of experience in bacteriology and has worked on mycobacteria, Lyme disease, and organisms that cause otitis media. He made key contributions for the determination of the whole genome DNA sequence of Lyme disease causing bacteria which has led to expedited evaluation of potential vaccine candidates against Lyme disease.  In his work with the US Army for 12 years, Dr. Lathigra worked with high impact BSL-3 category infectious disease agents Bacillus anthracis, Francisella tularensis and Yersinia pestis.[/vc_column_text][vc_separator css=”.vc_custom_1568666353309{padding-top: 60px !important;}”][vc_column_text]

Solange Gentz, Ph.D.
Program Director: Cell Culture

B.S. (1990) Pontificia Universidade Catolica de Minas Gerais, Brazil, Biology
M.S. (1993) Universidade Federal de Minas Gerais, BH- Brazil, Microbiology
Ph.D. (2011) Universidade Federal de Minas Gerais, BH-Brazil, Cell Biology

Also make changes: Dr. Gentz has 25+ years of experience with cell culture laboratories for mammalian, insect and primary cultures. Strong expertise in developing CHO/NS0 stable cell lines producing high levels of protein and antibody therapeutics suitable for commercial manufacturing. At Human Genome Sciences, successfully generated the stable cell line Belimumab®, FDA approved treatment for Lupus Erythematosus. At Medimmune she was also involved in generating NSO stable lines for the second-generation derivatives of Synagis, Palivizumab®. As a new member of the Zalgen’s team she will manage and oversee a cell culture laboratory fully dedicated to develop NS0/CHO stable cell lines for large scale production.[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/4″ el_id=”interior-sidebar”][vc_wp_custommenu title=”News & Events” nav_menu=”25″][vc_separator][vc_column_text]



Shopping Cart
Scroll to Top